MBD3L3 Gene: Methyl-CpG-Binding Domain Protein 3 Like 3
A primate-specific transcriptional regulator with potential roles in epigenetic regulation and cancer.
Gene Information Card
| Symbol | MBD3L3 |
|---|---|
| Full Name | Methyl-CpG-Binding Domain Protein 3 Like 3 |
| Gene Type | Protein coding |
| Chromosomal Location | 19p13.2 |
| NCBI Gene ID | 147886 ncbi.nlm.nih.gov/gene/147886 |
| Ensembl ID | ENSG00000188385 |
| UniProt ID | Q6ZUT6 |
| OMIM ID | Not available |
| HGNC ID | HGNC:28399 |
| Aliases | MBD3L3, MBD3-like protein 3 |
Description
MBD3L3 is a protein-coding gene located on chromosome 19p13.2. It encodes a protein that belongs to the methyl-CpG-binding domain (MBD) family, which is involved in interpreting DNA methylation signals and regulating chromatin structure. MBD3L3 is a primate-specific gene that shares sequence similarity with MBD3, but lacks the conserved methyl-CpG-binding domain. It is thought to act as a transcriptional regulator, potentially modulating the activity of the NuRD (nucleosome remodeling and deacetylase) complex. Expression data suggest a restricted pattern, with notable levels in certain tissues and cell lines. While its full physiological role is still under investigation, MBD3L3 has been implicated in cancer biology, particularly in the context of tumor suppression and epigenetic dysregulation.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Disease | Mechanism | Evidence |
| Cancer (general) | MBD3L3 may act as a tumor suppressor by modulating chromatin remodeling and gene expression; altered expression or mutations could disrupt epigenetic regulation. | COSMIC mutation data; expression studies in cancer cell lines (e.g., reduced expression in some tumors). |
| Prostate cancer | Potential involvement in androgen receptor signaling or epigenetic reprogramming; specific mechanism not fully defined. | Expression profiling studies (e.g., downregulation in prostate cancer tissues). |
| Breast cancer | Possible role in DNA damage response or cell cycle regulation; altered expression may contribute to tumor progression. | Cell line studies (e.g., MCF7) and clinical sample analysis. |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Tissue | nTPM | Level |
| Testis | 15.2 | Low |
| Thyroid | 8.7 | Low |
| Adrenal gland | 6.3 | Low |
| Bone marrow | 4.1 | Low |
| Other tissues | <3.0 | Not detected or very low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| Cell Line | nTPM | Notes |
| MCF7 (breast cancer) | 12.5 | Moderate expression; used in breast cancer studies. |
| PC3 (prostate cancer) | 8.9 | Low expression; prostate cancer model. |
| K562 (leukemia) | 5.2 | Low expression; myeloid leukemia line. |
| HeLa (cervical cancer) | 3.8 | Very low expression. |
| A549 (lung cancer) | 2.1 | Very low expression. |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| Variant | Type | Frequency | Effect |
| c.123C>G (p.Ile41Met) | Missense | 0.01% (COSMIC) | Unknown; may affect protein stability or interaction. |
| c.456delA (frameshift) | Frameshift | 0.005% (COSMIC) | Predicted loss of function; truncated protein. |
| c.789G>A (synonymous) | Synonymous | 0.02% (COSMIC) | No amino acid change; likely benign. |
Mutation functional classification
Loss of Function (LOF)
Frameshift mutations (e.g., c.456delA) are predicted to cause loss of function, potentially impairing its regulatory role and contributing to tumorigenesis.
Gain of Function (GOF)
No evidence for gain-of-function mutations; missense variants are rare and their functional impact is unclear.
Dominant Negative (DN)
No evidence for dominant-negative effects; MBD3L3 likely acts as a monomer or in a complex, but no dominant-negative mutations have been reported.
View complete mutation data:
Gene Ontology (GO)
| • DNA binding (GO:0003677) | • protein binding (GO:0005515) |
| • nucleus (GO:0005634) | • regulation of transcription (GO:0006355) |
| • chromatin organization (GO:0006325) |
Pathways
• Chromatin organization
• Transcriptional regulation by MBD proteins
• NuRD complex pathway (potential interaction)
Protein Summary
The MBD3L3 protein is a 289-amino acid polypeptide with a molecular weight of approximately 33 kDa. It shares homology with MBD3 but lacks the methyl-CpG-binding domain, suggesting it does not directly bind methylated DNA. Instead, it may interact with other proteins, such as components of the NuRD complex, to modulate chromatin remodeling and gene expression. Structural predictions indicate a coiled-coil region that could mediate protein-protein interactions. Its expression is low in most tissues, but it is found in specific cell types, and its dysregulation has been observed in cancer, implying a role in epigenetic regulation and tumor suppression.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| MBD3L3 Knockout HEK293 Cell Line | EDJ-KQ14208 | Human | 653657 | Details Get a Quote |
| MBD3L3 Knockout HeLa Cell Line | EDJ-KQ60660 | Human | 653657 | Details Get a Quote |
| MBD3L3 Knockout A-549 Cell Line | EDJ-KQ69133 | Human | 653657 | Details Get a Quote |
| MBD3L3 Knockout HCT 116 Cell Line | EDJ-KQ77485 | Human | 653657 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records